TY - JOUR
T1 - Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours
AU - Kaemmerer, Daniel
AU - Peter, Luisa
AU - Lupp, Amelie
AU - Schulz, Stefan
AU - Sänger, Jörg
AU - Prasad, Vikas
AU - Kulkarni, Harshad
AU - Haugvik, Sven Petter
AU - Hommann, Merten
AU - Baum, Richard Paul
PY - 2011/9
Y1 - 2011/9
N2 - Purpose: Somatostatin receptors (SSTR) are known for an overexpression in gastroenteropancreatic neuroendocrine tumours (GEP-NET). The aim of the present study was to find out if the receptor density predicted by the semiquantitative parameters generated from the static positron emission tomography (PET/CT) correlated with the in vitro immunohistochemistry using a novel rabbit monoclonal anti-SSTR2A antibody (clone UMB-1) for specific SSTR2A immunohistochemistry and polyclonal antibodies for SSTR1 and 3-5. Methods: Overall 14 surgical specimens generated from 34 histologically documented GEP-NET patients were correlated with the preoperative 68Ga-DOTA-NOC PET/CT. Quantitative assessment of the receptor density was done using the immunoreactive score (IRS) of Remmele and Stegner; the additional 4-point IRS classification for immunohistochemistry and standardized uptake values (SUV max and SUVmean) were used for PET/CT. Results: The IRS for SSTR2A and SSTR5 correlated highly significant with the SUVmax on the PET/CT (p<0.001; p< 0.05) and the IRS for SSTR2A with the SUV mean (p<0.013). The level of SSTR2A score correlated significantly with chromogranin A staining and indirectly to the tumour grading. Conclusion: The highly significant correlation between SSTR2A and SSTR5 and the SUV max on the 68Ga-DOTA-NOC PET/CT scans is concordant with the affinity profile of 68Ga-DOTA-NOC to the SSTR subtypes and demonstrates the excellent qualification of somatostatin analogues in the diagnostics of NET. This study correlating somatostatin receptor imaging using 68Ga-DOTA-NOC PET/CT with immunohistochemically analysed SSTR also underlines the approval of therapy using somatostatin analogues, follow-up imaging as well as radionuclide therapy.
AB - Purpose: Somatostatin receptors (SSTR) are known for an overexpression in gastroenteropancreatic neuroendocrine tumours (GEP-NET). The aim of the present study was to find out if the receptor density predicted by the semiquantitative parameters generated from the static positron emission tomography (PET/CT) correlated with the in vitro immunohistochemistry using a novel rabbit monoclonal anti-SSTR2A antibody (clone UMB-1) for specific SSTR2A immunohistochemistry and polyclonal antibodies for SSTR1 and 3-5. Methods: Overall 14 surgical specimens generated from 34 histologically documented GEP-NET patients were correlated with the preoperative 68Ga-DOTA-NOC PET/CT. Quantitative assessment of the receptor density was done using the immunoreactive score (IRS) of Remmele and Stegner; the additional 4-point IRS classification for immunohistochemistry and standardized uptake values (SUV max and SUVmean) were used for PET/CT. Results: The IRS for SSTR2A and SSTR5 correlated highly significant with the SUVmax on the PET/CT (p<0.001; p< 0.05) and the IRS for SSTR2A with the SUV mean (p<0.013). The level of SSTR2A score correlated significantly with chromogranin A staining and indirectly to the tumour grading. Conclusion: The highly significant correlation between SSTR2A and SSTR5 and the SUV max on the 68Ga-DOTA-NOC PET/CT scans is concordant with the affinity profile of 68Ga-DOTA-NOC to the SSTR subtypes and demonstrates the excellent qualification of somatostatin analogues in the diagnostics of NET. This study correlating somatostatin receptor imaging using 68Ga-DOTA-NOC PET/CT with immunohistochemically analysed SSTR also underlines the approval of therapy using somatostatin analogues, follow-up imaging as well as radionuclide therapy.
KW - Clone UMB-1
KW - Neuroendocrine tumour
KW - Somatostatin receptor imaging
KW - Somatostatin receptor immunohistochemistry
UR - http://www.scopus.com/inward/record.url?scp=80455174041&partnerID=8YFLogxK
U2 - 10.1007/s00259-011-1846-5
DO - 10.1007/s00259-011-1846-5
M3 - Article
C2 - 21626438
AN - SCOPUS:80455174041
SN - 1619-7070
VL - 38
SP - 1659
EP - 1668
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 9
ER -